Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 May 5;30(160):200227.
doi: 10.1183/16000617.0227-2020. Print 2021 Jun 30.

New developments in locally advanced nonsmall cell lung cancer

Rudolf M Huber  1   2 , Diego Kauffmann-Guerrero  3   2 , Hans Hoffmann  4 , Michael Flentje  5
Affiliations

New developments in locally advanced nonsmall cell lung cancer

Rudolf M Huber et al. Eur Respir Rev. .

Abstract

Locally advanced nonsmall cell lung cancer, due to its varying prognosis, is grouped according to TNM stage IIIA, IIIB and IIIC. Developments over the last 3 years have been focused on the integration of immunotherapy into the combination treatment of a locally definitive therapy (surgery or radiotherapy) and chemotherapy. For concurrent chemoradiotherapy, consolidation therapy with durvalumab was established. Adjuvant targeted therapy has again gained increasing interest. In order to adapt treatment to the specific stage subgroup and its prognosis, fluorodeoxyglucose positron emission tomography/computed tomography and pathological evaluation of the mediastinum are important. Tumours should be investigated for immunological features and driver mutations. Regarding toxicity, evaluation of pulmonary and cardiac function, as well as symptoms and quality of life, is of increasing importance. To improve the management and prognosis of this heterogeneous entity, clinical trials and registries should take these factors into account.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: R.M. Huber reports grants from German Ministry of Education and Research and AstraZeneca, and personal fees from AstraZeneca, BMS, Bayer, Boehringer Ingelheim, Lilly, MSD, Takeda, Pfizer, Novartis, Roche, Celgene, Abbvie and Tesaro, outside the submitted work. Conflict of interest: D. Kauffmann-Guerrero reports personal fees from AstraZeneca, BMS, Roche, MSD, Pfizer and Boehringer Ingelheim, outside the submitted work. Conflict of interest: H. Hoffmann has nothing to disclose. Conflict of interest: M. Flentje has nothing to disclose.

Figures

FIGURE 1
FIGURE 1
Proposal for further strategies in clinical trials and registries about the management of locally advanced nonsmall cell lung cancer (NSCLC). FDG: fluorodeoxyglucose; PET: positron emission tomography; CT: computed tomography; PS: performance status; PFS: progression-free survival.
See this image and copyright information in PMC

References

    1. Goldstraw P, Chansky K, Crowley J, et al. . The IASLC Lung Cancer Staging Project: proposals for revision of the TNM stage groupings in the forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. J Thorac Oncol 2016; 11: 39–51. doi:10.1016/j.jtho.2015.09.009 - DOI - PubMed
    1. Huber RM, De Ruysscher D, Hoffmann H, et al. . Interdisciplinary multimodality management of stage III nonsmall cell lung cancer. Eur Respir Rev 2019; 28: 190024. doi:10.1183/16000617.0024-2019 - DOI - PMC - PubMed
    1. Postmus PE, Kerr KM, Oudkerk M, et al. . Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2017; 28: Suppl. 4: iv1–iv21. doi:10.1093/annonc/mdx222 - DOI - PubMed
    1. Kris MG, Gaspar LE, Chaft JE, et al. . Adjuvant systemic therapy and adjuvant radiation therapy for stage I to IIIA completely resected non–small-cell lung cancers: American Society of Clinical Oncology/Cancer Care Ontario Clinical Practice Guideline update. J Clin Oncol 2017; 35: 2960–2974. doi:10.1200/JCO.2017.72.4401 - DOI - PubMed
    1. Putora PM, Leskow P, McDonald F, et al. . International guidelines on stage III N2 nonsmall cell lung cancer: surgery or radiotherapy? ERJ Open Res 2020; 6: 00159-2019. doi:10.1183/23120541.00159-2019 - DOI - PMC - PubMed

MeSH terms